Murdoch David R.
Department of Pathology, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand.
Curr Infect Dis Rep. 2004 Feb;6(1):43-49. doi: 10.1007/s11908-004-0023-4.
High-altitude illness is the collective term for acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). These syndromes can affect unacclimatized travelers shortly after ascent to high altitude (especially higher than 2500 m). AMS is relatively common and usually is mild and self-limiting; HACE and HAPE are uncommon but life-threatening. Gradual ascent is the best strategy for preventing or minimizing high-altitude illness, although chemoprophylaxis may be useful in some situations. Acetazolamide remains the chemoprophylactic agent of choice, although other drugs, such as gingko biloba, are being investigated. Immediate descent remains the cornerstone of treatment for HACE and HAPE, although pharmacologic and hyperbaric therapies may facilitate this process.
高原病是急性高原病(AMS)、高原脑水肿(HACE)和高原肺水肿(HAPE)的统称。这些综合征可在未适应高原环境的旅行者登高后不久(尤其是高于2500米时)影响他们。急性高原病相对常见,通常症状较轻且具有自限性;高原脑水肿和高原肺水肿不常见,但可危及生命。尽管在某些情况下化学预防可能有用,但逐步登高仍是预防或减轻高原病的最佳策略。乙酰唑胺仍是首选的化学预防药物,不过其他药物,如银杏叶,也在研究之中。尽管药物治疗和高压氧治疗可能有助于这一过程,但立即下山仍是高原脑水肿和高原肺水肿治疗的基石。